Ipsen Aktie

103,20 EUR +0,10 EUR +0,10 %

02.06.2025

STU

102,50 EUR -1,30 EUR -1,25 %

02.06.2025

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.8,58 Mrd. EUR

KGV26,49Div. Rendite1,26%

WKNA0ESMG

ISINFR0010259150

SymbolIPSEF

Ipsen Aktien News

Sortieren:Datum Meistgelesen

02.06.25GlobeNewswireIpsen S.A. - Initiation of the share buy-back program

31.05.25GlobeNewswireLate-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma

21.05.25GlobeNewswireIpsen S.A. - Annual General Meeting held on 21 May 2025

WerbungIpsen-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

12.05.25GlobeNewswireIpsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

07.05.25GlobeNewswireLate-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary b

06.05.25GlobeNewswireIpsen appoints Laura Réveillon as EVP, Strategy & Transformation

30.04.25GlobeNewswireIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting

24.04.25GlobeNewswireLate-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

16.04.25GlobeNewswireIpsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

14.04.25GlobeNewswireIpsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

08.04.25GlobeNewswireIpsen publishes its 2024 Universal Registration Document

19.03.25GlobeNewswireIpsen announces issuance of €500 million inaugural Rated Public Bond

12.03.25GlobeNewswireIpsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

06.03.25GlobeNewswireIpsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

21.02.25GlobeNewswireIpsen S.A. publishes its 2024 consolidated financial statements

13.02.25GlobeNewswireIpsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

06.02.25GlobeNewswireIpsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

07.01.25GlobeNewswireIpsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07.01.25GlobeNewswireIpsen - Half year statement - 2024 12 31

09.12.24GlobeNewswireIpsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

03.12.24GlobeNewswireIpsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

18.11.24GlobeNewswireBylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

15.11.24GlobeNewswireIqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

07.11.24GlobeNewswireIpsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

23.10.24GlobeNewswireIpsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

14.10.24GlobeNewswireIpsen receives its second Shingo Prize for operational excellence

09.10.24GlobeNewswireIpsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

23.09.24GlobeNewswireIpsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

20.09.24GlobeNewswireIpsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

16.09.24GlobeNewswireFinal results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

15.09.24GlobeNewswireIpsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

04.09.24GlobeNewswireIpsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

13.08.24GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024

06.08.24GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024

05.08.24GlobeNewswireIpsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

30.07.24GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024

26.07.24GlobeNewswireIpsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases

25.07.24GlobeNewswireIpsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)

25.07.24GlobeNewswireIpsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

25.07.24GlobeNewswireIpsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Ipsen News

Ipsen News: auf dieser Seite finden Sie alle Ipsen News und Nachrichten zur Ipsen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ipsen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ipsen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.